Resources Repository
-
ReportPublication 2018Understanding the Economics of Microbial Threats: Proceedings of a Workshop
This report follows a June 2018, Forum on Microbial Threats that was held at the …
This report follows a June 2018, Forum on Microbial Threats that was held at the National Academies of Sciences, Engineering, and Medicine. This was a 1.5-day public workshop with the goal being an assessment of the current understanding of the interaction of infectious disease threats and economic activity in order to suggest future areas of research. This workshop built on prior work of the Forum and aimed to build more mutual understanding between those in…
Technology Assessment | Economics/Finance | Global | Infectious Diseases | Health Outcomes | Evidence Synthesis | Policy/Regulation | Global Governance | Clinical Care | Business/Industry | Health/Medicine -
ArticlePublication 2017When Cost-Effective Interventions Are Unaffordable
Many health interventions deemed cost-effective are not affordable. Despite the importance of affordability to policymakers, …
Many health interventions deemed cost-effective are not affordable. Despite the importance of affordability to policymakers, little of the cost-effectiveness literature in global health addresses this issue. Budget impact analysis (BIA) describes an intervention's short-term costs and savings from the payer's perspective. This paper assesses the current use of budget impact analysis (BIA) and cost-effectiveness analysis (CEA) in health economic assessments conducted for low- and middle-income countries (LMICs). The authors recommend steps researchers and policymakers can…
Cost-Effectiveness Analysis | Economics/Finance | Global | Infectious Diseases | Priority Setting/Ethics | Costing Methods | Chronic Disease/Risk | Health Systems | Government/Law | Health/Medicine | Science/Technology -
ReportPublication 2017DCP3: Major Infectious Diseases
This report from the World Bank is the sixth volume of the Disease Control Priorities, …
This report from the World Bank is the sixth volume of the Disease Control Priorities, third edition (DCP3) series and examines the burden of infectious diseases, which remain a leading cause of death globally, especially for children and adolescents. This report identifies feasible and cost-effective platforms to prevent and treat diseases like HIV/AIDS, other sexually transmitted infections, tuberculosis, malaria, adult febrile illness, viral hepatitis, and tropical diseases. This volume also emphasizes the importance of addressing…
Cost-Effectiveness Analysis | Economics/Finance | Global | Infectious Diseases | Costing Methods | Health Outcomes | Evidence Synthesis | Health Systems | Global Governance | Health/Medicine -
ArticlePublication 2016UHC for Mental, Neurological, and Substance Use Disorders: An Extended CEA
This study uses extended cost effectiveness analysis (ECEA) to analyze the impacts of universal public …
This study uses extended cost effectiveness analysis (ECEA) to analyze the impacts of universal public finance (UPF) on epilepsy, schizophrenia, and depression in India and Ethiopia. The Ethiopian government has launched a National Mental Health Strategy which explicitly recognizes the importance of an efficient, equitable scale-up of mental health care within a broader, ongoing effort to increase levels of health insurance in the general population. The analyses show that enhanced coverage of effective treatment leads…
Cost-Effectiveness Analysis | Economics/Finance | Global | Social Determinants | Priority Setting/Ethics | Mental Health | Health Systems | Health/Medicine -
ArticlePublication 2016Using Top-Down and Bottom-Up Costing Approaches in LMICs
In the absence of routine cost data collection, estimating the incremental costs of scaling-up novel …
In the absence of routine cost data collection, estimating the incremental costs of scaling-up novel technologies in low-income and middle-income countries is a methodologically challenging and substantial empirical undertaking. Using the example of costing the scale-up of Xpert Mycobacterium tuberculosis (MTB)/resistance to riframpicin (RIF) in South Africa, the authors estimate costs, by applying two distinct approaches of bottom-up and top-down costing, together with an assessment of processes and capacity. The unit costs measured using the…
Cost-Effectiveness Analysis | Economics/Finance | Global | Infectious Diseases | Costing Methods | Health Systems | Health/Medicine -
ReviewPublication 2014Valuing Vaccination
Vaccination has led to remarkable health gains over the last century. However, large coverage gaps …
Vaccination has led to remarkable health gains over the last century. However, large coverage gaps remain, which will require significant financial resources and political will to address. In recent years, a compelling line of inquiry has established the economic benefits of health, at both the individual and aggregate levels. Most existing economic evaluations of particular health interventions fail to account for this new research, leading to potentially sizable undervaluation of those interventions. In line with…
Benefit-Cost Analysis | Economics/Finance | Global | Infectious Diseases | Preferences/Values | Priority Setting/Ethics | Costing Methods | Health Systems | Health/Medicine